Close Menu

    Subscribe to Updates

    Get the latest information from JBUON.

    What's Hot

    Two Cases of Pancreatic Metastases from Renal Cell Carcinoma and Review of the Literature

    April 17, 2025

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    March 14, 2025

    Surgical Treatment of Right Atrial Metastasis of the Malignant Melanoma: A Case Report

    March 6, 2025
    Facebook X (Twitter) Instagram
    JBUONJBUON
    • How to Submit
    • Author Guidelines
    Facebook X (Twitter) Instagram
    SUBMIT
    • Home
    • Browse Issues
      • In Press
      • Current Issue
      • Archives
    • About Journal
      • Journal Information
      • Editorial Board
      • Bibliographic Listings
      • Editorial Policy
      • Ethics and Malpractice Statement
    • For Authors
      • How To Submit
      • Submit Article
      • Downloads
    • Contact
    JBUONJBUON
    Home»Issues»Volume 26, Issue 6»Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: is it too early to reach conclusion?
    Volume 26, Issue 6

    Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: is it too early to reach conclusion?

    November 30, 2021Updated:April 29, 20242 Mins Read
    Share
    Facebook Twitter Email

    Ahmet N. Sanli1, Kadri Altundag2

    1Department of General Surgery, Silivri State Hospital, Istanbul, Turkey.

    2MKA Breast Cancer Clinic, Tepe Prime, Ankara, Turkey.

    Abstract

    Dear Editor,

    Breast cancer is the most common cancer in women worldwide. Understanding the biology of this tumor is a prerequisite for selecting an appropriate treatment. Cell cycle alterations are seen in many cancers, such as breast cancer. Newly popular targeted agents in breast cancer are cyclin-dependent kinase inhibitors (CDKIs) (palbociclib, ribociclib, abemaciclib) which are agents inhibiting the function of cyclin-dependent kinases (CDKs) [1]. On October 12th 2021, the United States Food and Drug Administration (FDA) approved abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of ≥20% as determined by an FDA-approved test. A pivotal adjuvant trial concluded that abemaciclib + endocrine therapy significantly improved invasive disease-free survival (IDFS) in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, with an acceptable safety profile [2]. At the additional follow-up analysis, with 27 months median follow-up and 90% of patients off treatment, IDFS (p<0.0001) and distant relapse-free survival (DRFS) (p<0.0001) benefit was maintained. However, median follow-up time is still quite short for a study of ER+ adjuvant therapy, where the majority of recurrences and deaths occur after 5 years in many studies. Furthermore, this class of cyclin-dependent kinase 4 and 6 is likely cytostatic, rather than cytocidal. It means that it blocks cell proliferation rather than leading to cell senescence and apoptosis. Overall survival was a secondary outcome measure for the monarchE study [2] . This survival information was not included in the recent study, due to immaturity of the data. Whether the survival curves for combination therapy will come together with those for endocrine therapy alone once patients stop taking the drug is still common concern and needs to be investigated.

    Full Text: PDF

    Letter to the Editor
    Previous ArticleRegular daily weighted Hula-Hooping might reduce central adiposity leading to decreased pre- and postmenopausal breast cancers risk
    Next Article Inmate cancer patient – Highlighting the importance of a holistic approach to oncological care

    Related Articles

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    Volume 26, Issue 6

    Induction chemotherapy in head and neck cancers – old actors, new horizons

    Volume 26, Issue 6

    Caspases-related apoptosis in meningiomas

    Volume 26, Issue 6
    Don't Miss
    Volume 27, 2024

    Two Cases of Pancreatic Metastases from Renal Cell Carcinoma and Review of the Literature

    April 17, 2025

    Dimosthenis Chrysikos1, Spiros Delis2, Charina Triantopoulou2, Evgenia Charitaki2, Nikos Kokoroskos2, Nikolaos Taprantzis1*, Amir Shihada1, Konstantinos…

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    March 14, 2025

    Surgical Treatment of Right Atrial Metastasis of the Malignant Melanoma: A Case Report

    March 6, 2025

    Abdominal Aortic Aneurysm and Radiation Therapy

    October 28, 2024
    Our Picks

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    December 1, 2021

    Chromosomal instability landscape in uveal melanoma

    December 1, 2021

    Biomarkers and common oral cancers: Clinical trial studies

    December 1, 2021

    Subscribe to Updates

    About Us
    About Us

    Journal of BUON (Print ISSN: 1107-0625, Electronic ISSN: 2241-6293) is an independent Open Access Journal, published by BAKIS Productions LTD, and appears exclusively on the internet. It is covered/indexed in Current Awareness in Biological Sciences (BIO-BASE), EMBASE/Excerpta Medica.
    We're accepting new manuscripts right now.

    Email Us: editorial_office@jbuon.com
    Contact: Available soon

    Editorial Picks

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    December 1, 2021

    Chromosomal instability landscape in uveal melanoma

    December 1, 2021

    Biomarkers and common oral cancers: Clinical trial studies

    December 1, 2021
    Get in Touch

    Editor-in-Chief
    Athanasios E. Athanasiou,
    Department of Medical Oncology,
    Metaxa Cancer Hospital, Botassi 51, 18537, Piraeus, Greece
    Editorial Office: editorial_office@jbuon.com

    Publishing support
    EManuscript Technologies
    # 9, First Floor, Vinnse Towers
    Wheeler Road Extension, St. Thomas Town, Bangalore 560 084, INDIA
    E: journals@emanuscript.in 
    W : www.emanuscript.in

     

    • Home
    • Author Guidelines
    • Site Map
    • Contact Us
    © 2025 JBUON Powered by EManuscript.

    Type above and press Enter to search. Press Esc to cancel.